EHA 2023 | Journaal Multipel Myeloom (MM)

In dit journaal bespreekt prof. dr. Sonja Zweegman haar selectie van het belangrijkste EHA-nieuws op het gebied van multipel myeloom. Dit jaar stond dat nieuws volledig in het teken van CAR-T-celtherapie en bispecifieke antilichamen. U hoort meer hierover in dit journaal.

De volgende abstracts komen in dit journaal ter sprake: 

CAR-T celtherapie

• S202 - CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
• S100 - First phase 3 results from CARTITUDE-4: cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma
• S195 - Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class–exposed (tce) relapsed and refractory multiple myeloma (RRMM): a KARMMA-3 analysis in high-risk subgroups
• S193 - BMS-986393 (CC-95266), a G protein–coupled receptor class C group 5 member D (GPRC5D)–targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Results from a phase 1 study

BCMA-gerichte bispecifieke antilichamen

• S196 - Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients with relapsed/refractory multiple myeloma: extended follow up and biweekly administration from MAGNETISMM-3
• P870 - Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MAGNETISMM studies

Combinatiestrategieën

• S190 - First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
• S192 -Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated TRIMM-2 results